Article
Oncology
C. Robert, K. D. Lewis, R. Gutzmer, D. Stroyakovskiy, H. Gogas, S. Protsenko, R. P. Pereira, T. Eigentler, P. Rutkowski, L. Demidov, I Caro, H. Forbes, K. Shah, Y. Yan, H. Li, G. A. McArthur, P. A. Ascierto
Summary: The triplet combination therapy of atezolizumab, vemurafenib, and cobimetinib demonstrated improved progression-free survival in patients with BRAF-mutated advanced melanoma. Exploratory biomarker analyses identified potential predictors including tumor mutational burden, interferon-gamma expression, and PD-L1 expression.
ANNALS OF ONCOLOGY
(2022)
Article
Dermatology
Mario Mandala, Giuseppe Palmieri, Vienna Ludovini, Sara Baglivo, Francesca Marasciulo, Francesca Castiglione, Alessio Gili, Simona Osella Abate, Marco Rubatto, Rebecca Senetta, Gianluca Avallone, Simone Ribero, Luca Romano, Nicola Pimpinelli, Vincenzo de Giorgi, Fausto Roila, Marina Pisano, Milena Casula, Antonella Manca, Maria Cristina Sini, Daniela Massi, Pietro Quaglino
Summary: The prognostic impact of variant allele frequency (VAF) on clinical outcome in metastatic melanoma patients receiving BRAF and MEK inhibitors is still unclear. This study found that high VAF is an independent poor prognostic factor in these patients.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Nadine Kretschmer, Christin Durchschein, Antje Hufner, Beate Rinner, Birgit Lohberger, Rudolf Bauer
Summary: In this study, a novel shikonin derivative called SK119 was synthesized and evaluated for its pharmacological effects on human melanoma cells. SK119 exhibited promising activity in a nano-molar range and showed synergistic effects with vemurafenib and cobimetinib, two clinically used melanoma therapeutics. Further research indicates the potential of SK119 in melanoma therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
H. Gogas, B. Dreno, J. Larkin, L. Demidov, D. Stroyakovskiy, Z. Eroglu, P. Francesco Ferrucci, J. Pigozzo, P. Rutkowski, J. Mackiewicz, I Rooney, A. Voulgari, S. Troutman, B. Pitcher, Y. Guo, Y. Yan, M. Castro, S. Mulla, K. Flaherty, A. Arance
Summary: The combination therapy of MEK inhibitors and immune checkpoint inhibitors did not show improved progression-free survival compared to monotherapy with pembrolizumab in patients with previously untreated BRAF(V600) wild-type advanced melanoma.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Jesper van Breeschoten, Michel W. J. M. Wouters, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jan-Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Karijn P. M. Suijkerbuijk, Willeke A. M. Blokx, Bert-Jan J. ten Tije, Astrid A. M. van der Veldt, Art Vreugdenhil, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh
Summary: The study showed that in advanced melanoma patients with BRAF(V600) mutation, first-line anti-PD-1 monotherapy had better survival rates and efficacy compared to BRAF/MEK inhibitors, making it the preferred treatment option for these patients.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Katharina C. Kaehler, Ralf Gutzmer, Friedegrund Meier, Lisa Zimmer, Markus Heppt, Anja Gesierich, Kai-Martin Thoms, Jochen Utikal, Jessica C. Hassel, Carmen Loquai, Claudia Pfoehler, Lucie Heinzerling, Martin Kaatz, Daniela Goeppner, Annette Pflugfelder, Ann-Sophie Bohne, Imke Satzger, Lydia Reinhardt, Jan-Malte Placke, Dirk Schadendorf, Selma Ugurel
Summary: The development of an early exanthema within 6 weeks after treatment start indicates a favorable therapy outcome upon vemurafenib plus cobimetinib. Patients presenting with an early exanthema should therefore be treated with adequate supportive measures to provide that patients can stay on treatment. In the COBIVEM cohort, patients with a mild early exanthema had a superior survival outcome compared to patients with a severe or non early exanthema.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Ma del Carmen Alamo, Sebastian Ochenduszko, Guillermo Crespo, Monica Corral, Juana Oramas, Pilar Sancho, Javier Medina, Fernando Garicano, Pedro Lopez, Begona Campos Balea, Analia Rodriguez Garzotto, Eva Munoz-Couselo
Summary: The study evaluated the efficacy of combination therapy with vemurafenib/cobimetinib in terms of durability, finding that one-third of patients achieved a sustained complete response. Factors such as body mass index may influence the durability of the response in patients with advanced melanoma.
ONCOTARGETS AND THERAPY
(2021)
Article
Oncology
Nicolas Meyer, David Perol, Anne-Benedicte Duval-Modeste, Laila El Adaoui, Yoann Lelarge, Ralph Niarra, Christine Mateus
Summary: This study provides real-world outcomes in France for the vemurafenib-cobimetinib combination available in patients with BRAF-mutant-advanced melanoma. Our data tend to confirm in the real-life setting that this combination therapy is effective in such patients, with a safety profile consistent with previous interventional studies.
Article
Oncology
Shahneen Sandhu, Victoria Atkinson, Maria Gonzalez Cao, Theresa Medina, Ainara Soria Rivas, Alexander M. Menzies, Ivor Caro, Louise Roberts, Yuyao Song, Yibing Yan, Yu Guo, Cloris Xue, Georgina V. Long
Summary: The efficacy and safety of cobimetinib plus atezolizumab in the treatment of advanced BRAFV600 wild-type melanoma patients who failed prior anti-PD-1 therapy were evaluated. The results showed limited activity of this combination therapy in patients with disease progression on or after prior anti-PD-1 therapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen, Melissa Hamilton, Shien Guo, Ling Shi, Sarah Keidel, Georgina Long
Summary: The RELATIVITY-047 trial demonstrates that the fixed-dose combination of nivolumab plus relatlimab improves progression-free survival in patients with advanced melanoma while maintaining stable health-related quality of life. Although the combination treatment is associated with a higher incidence of severe adverse events, patients' discomfort with these events is low, supporting NIVO + RELA as a first-line treatment option.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Andreas M. Schmitt, Lucy Dumas, James Larkin
Summary: The combination of atezolizumab, cobimetinib, and vemurafenib demonstrates superior progression-free survival in patients with metastatic melanoma compared to cobimetinib and vemurafenib alone. Triplet therapy may be considered in urgent situations for disease control, when BRAF/MEK inhibition is chosen as the first-line treatment over immune checkpoint inhibition. However, further follow-up and comparison with ipilimumab and nivolumab combination are needed to determine the future role of this combination.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Article
Oncology
Paolo. A. Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, Pietro Quaglino, Francesco Spagnolo, Massimo Guidoboni, Michele Del Vecchio, Ketty Peris, Paola Queirolo, Luisa Fioretto, Corrado Caraco, Miriam Paone, Antonio Sorrentino, Mariaelena Capone, Diana Giannarelli, Gerardo Ferrara, Daniela Massi, Claudia Trojaniello
Summary: This study aims to investigate the efficacy of neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma. The study is a phase II, open-label, non-comparative trial in patients with stage IIIB/C/D surgically resectable melanoma. It is expected that the combination of neoadjuvant and adjuvant treatment may reduce the incidence of relapse and improve survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Binghe Xu, Wei Li, Qingyuan Zhang, Qiao Li, Xiaojia Wang, Huiping Li, Tao Sun, Yongmei Yin, Hong Zheng, Jifeng Feng, Huaqi Zhu, Asna Siddiqui, Harrison Macharia, Adam Knott
Summary: The PUFFIN study in Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer showed that the efficacy and safety of pertuzumab plus trastuzumab and docetaxel were consistent with CLEOPATRA. This study contributes to the evidence supporting the favorable benefit-risk profile of pertuzumab in Chinese patients.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Medicine, General & Internal
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.
Article
Oncology
Paul B. Googe, Stamatios Theocharis, Alexandros Pergaris, Haocheng Li, Yibing Yan, Edward F. McKenna, Stergios J. Moschos
Summary: A retrospective tumor tissue analysis was conducted to evaluate the theragnostic significance of tumor-infiltrating lymphocytes (TILs) and melanoma cell proliferation. The study found a significant association between high peritumoral CD8 TIL score and progression-free survival (PFS), while high Ki67 proliferation index and TIL score were not significantly associated with antitumor response.
CURRENT PROBLEMS IN CANCER
(2022)
